Pulmonary embolism in an adolescent girl with negative ACLA systemic lupus erythematosus (SLE)
A case report
Keywords:
pulmonary thromboembolism, ACLA, systemic lupus erythematosus (SLE)Abstract
Pulmonary involvement is a common manifestation in systemic lupus erythematosus (SLE), whereas pulmonary thromboembolism (PTE) is rarely seen in SLE. PTE related to anti-phospholipid antibody syndrome (APS) is also a rare disease. We have reported a 13-year-old female diagnosed with SLE Two years ago, who is being treated with hydroxychloroquine and prednisolone. She presented with shortness of breath, dry cough, and fever about two weeks prior to admission. She was initially admitted with the diagnosis of pneumonia, but no clinical improvement was seen she was given antibiotics. Hemoptysis was added to her symptoms, so spiral high resolution computed tomography (HRCT) of the lungs was requested, and it indicated patchy consolidations bilaterally. With suspicion of pulmonary thromboembolism (PTE), spiral computed tomography angiography of pulmonary vessels was done, revealing PTE. After initiation of anti-coagulants, her clinical condition and respiratory status improved significantly. We present a rare case of SLE where only lupus anti-coagulant test was abnormal while other tests, such as anti-cardiolipin antibody and anti-phospholipid antibody were normal. Therefore, we can conclude that clinical suspicion had the main role in diagnosis in our case, as it has in medicine.
References
Benseler SM, Silverman ED. Systemic lupus erythematosus. Pediatr Clin North Am. 2005; 52(2): 443-67.
PMID: 15820375.
Gladman DD, Urowitz MB. Venous syndromes and pulmonary embolism in systemic lupus erythematosus.
Ann Rheum Dis. 1980; 39(4): 340-3. PMID: 7436559.
Müller C, Willaschek C, Borst M, Buchhorn R. Recurrent pulmonary embolism in a boy with
antiphospholipid syndrome. Case Reports in Clinical Medicine, 2, 310-314. 2013; 2(5): 310-14. doi:
4236/crcm.2013.25083.
Avcin T, Cimaz R, Silverman ED, Cervera R, Gattorno M, Garay S, et al. Pediatric antiphospholipid
syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics. 2008;
(5): e1100-7. doi: 10.1542/peds.2008-1209, PMID: 18955411.
Afeltra A, Vadacca M, Conti L, Galluzzo S, Mitterhofer AP, Ferri GM, et al. Thrombosis in systemic lupus
erythematosus: congenital and acquired risk factors. Arthritis Rheum. 2005; 53(3): 452-9. doi:
1002/art.21172, PMID: 15934123.
Manger K, Manger B, Repp R, Geisselbrecht M, Geiger A, Pfahlberg A, et al. Definition of risk factors for
death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with
systemic lupus erythematosus. Ann Rheum Dis. 2002; 61(12): 1065-70. doi: 10.1136/ard.61.12.1065.
PMID: 12429536, PMCID: PMC1753955
Tarr T, Lakos G, Bhattoa HP, Shoenfeld Y, Szegedi G, Kiss E. Analysis of risk factors for the development
of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus. 2007; 16(1): 39- 45. doi: 10.1177/0961203306074767, PMID: 17283584.
Shah NM, Khamashta MA, Atsumi T, Hughes GR. Outcome of patients with anticardiolipin antibodies: a
year follow-up of 52 patients. Lupus. 1998; 7(1): 3-6. PMID: 9493141.
Berube C, Mitchell L, Silverman E, David M, Saint Cyr C, Laxer R, et al. The relationship of
antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus
erythematosus: a cross-sectional study. Pediatr Res. 1998; 44(3): 351-6. doi: 10.1203/00006450- 199809000-00014, PMID: 9727712.
Fei Y, Shi X, Gan F, Li X, Zhang W, Li M, et al. Death causes and pathogens analysis of systemic lupus
erythematosus during the past 26 years. Clin Rheumatol. 2014; 33(1): 57-63. doi: 10.1007/s10067-013- 2383-3.
Agmon-Levin N, Shoenfeld Y. The spectrum between antiphospholipid syndrome and systemic lupus
erythematosus. Clin Rheumatol. 2014; 33: 293–5. doi: 10.1007/s10067-014-2486-5.
Published
Issue
Section
License
Copyright (c) 2022 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.